** Shares of Innovent Biologics 1801.HK climb 3.2% to HK$36.65, on track for the biggest one-day pct rise since Dec. 9
** Innovent Biologics says China's National Medical Products Administration (NMPA) has approved second New Drug Application (NDA) of DOVBLERON, which is an oral ROS1 inhibitor for treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer
** Says the NDA was accepted by the U.S. Food and Drug Administration for priority review in December 2024
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both gain 0.4% while Hang Seng Index .HSI adds 0.2%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.